Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to HER2-Positive Gastric Cancer
Related studies linked through entity extraction aliases.
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Status
- RECRUITING
- Phase
- N/A
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Status
- RECRUITING
- Phase
- PHASE3
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
- Status
- COMPLETED
- Phase
- NA
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
- Status
- TERMINATED
- Phase
- PHASE1